Fresenius Medical Care AG & Co. KGaA (ETR:FME) PT Set at €92.00 by UBS Group

UBS Group set a €92.00 ($106.98) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report released on Thursday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also weighed in on the stock. Goldman Sachs Group set a $13.00 price objective on shares of Ford Motor and gave the company a buy rating in a report on Thursday, June 13th. Morgan Stanley reiterated an overweight rating and set a C$125.00 price objective on shares of Intact Financial in a report on Wednesday, May 15th. Kepler Capital Markets set a €80.00 ($93.02) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Thursday, May 2nd. Independent Research set a €74.00 ($86.05) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Monday, June 17th. Finally, Jefferies Financial Group reiterated a buy rating and set a GBX 99 ($1.29) price objective on shares of in a report on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of €82.57 ($96.01).

Shares of ETR FME opened at €69.70 ($81.05) on Thursday. The firm’s 50-day moving average is €68.10. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67). The firm has a market capitalization of $21.28 billion and a price-to-earnings ratio of 10.85. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 100.05.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Article: Forex

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.